1147-56-4
1147-56-4 結構式
基本信息
1-(2-噻唑偶氮)-2-萘酚
1-(2-噻唑基偶氮)-2-萘酚
1-(2'-噻唑基偶氮)-2-萘酚
2-(2-羥基-1-萘基偶氮)噻唑
1-(2-聯(lián)氮噻吩)-2-萘酚
2-(2-HYDROXY-1-NAPHTHYLAZO)THIAZOLE
TAN
1-(2’-Thiazolylazo)-β-naphtho
1-(2-thiazolylazo)-2-naphthaleno
1-(2-thiazolylazo)-2-Naphthalenol
1-(thiazol-2-ylazo)-2-naphthol
1-(2'-Thiazolylazo)-β-naphthol
TAN [=1-(2-Thiazolylazo)-2-naphthol] [Spectrophotometric reagent for transition metals]
2-(2-Hydroxy-1-naphthylazo)thiazole, TAN
1-(Thiazole-2-ylazo)-2-naphthol
1-(Thiazole-2-ylazo)naphthalene-2-ol
1-[(Thiazole-2-yl)azo]-2-naphthol
Nitrilotantalum(III)
物理化學性質
安全數(shù)據
| 報價日期 | 產品編號 | 產品名稱 | CAS號 | 包裝 | 價格 |
| 2026/07/06 | B24011 | 1-(2-聯(lián)氮噻吩)-2-萘酚, 98% 1-(2-Thiazolylazo)-2-naphthol, 98% | 1147-56-4 | 5g | 1154元 |
| 2026/06/06 | A5003 | TAN[=1-(2-噻唑偶氮)-2-萘酚][過渡金屬類用分光光度試劑] TAN [=1-(2-Thiazolylazo)-2-naphthol] [Spectrophotometric reagent for transition metals] | 1147-56-4 | 1G | 400元 |
| 2026/06/06 | A5003 | TAN[=1-(2-噻唑偶氮)-2-萘酚][過渡金屬類用分光光度試劑] TAN [=1-(2-Thiazolylazo)-2-naphthol] [Spectrophotometric reagent for transition metals] | 1147-56-4 | 5G | 1270元 |
常見問題列表
IC50: 30 to 400 nM (ERG-positive cancer cells)
NSC139021 selectively inhibits growth of ERGpositive cancer cell lines with minimal effect on normal prostate or endothelial cells or ERG-negative tumor cell lines. The IC 50 of NSC139021 for cell growth inhibition of responsive cell lines range between 30 nM to 400 nM. Combination of NSC139021 with enzalutamide shows additive effects in inhibiting growth of VCaP cells. A screen of kinases reveal that NSC139021 directly bound the ribosomal biogenesis regulator atypical kinase RIOK2 and induces ribosomal stress signature.
NSC139021 treatment inhibits growth of ERG-positive VCaP tumor xenografts with no apparent toxicity. Significant (P<0.05, P<0.005) inhibition of tumor growth is noted at day 26 in treatment groups indicating 44% (100 mg/kg) and 65% (150 mg/kg) reduction of tumor burden. At 100 mg/kg and 150 mg/kg, no apparent toxicity including weight loss, lethargy, diarrhea, loss of appetite, respiratory distress, or overall drug related toxicity is observed. .